MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate, and what generic alternatives are available?
Magnesium Hydroxide And Omeprazole And Sodium Bicarbonate is a drug marketed by Santarus and is included in one NDA.
The generic ingredient in MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE is magnesium hydroxide; omeprazole; sodium bicarbonate. There is one drug master file entry for this compound. Additional details are available on the magnesium hydroxide; omeprazole; sodium bicarbonate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE?
- What are the global sales for MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE?
- What is Average Wholesale Price for MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE?
Summary for MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 1 |
| DailyMed Link: | MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE at DailyMed |
Recent Clinical Trials for MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Bausch Health Americas, Inc. | Phase 4 |
| Yvonne Romero | Phase 4 |
| Valeant Pharmaceuticals International, Inc. | Phase 4 |
See all MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE clinical trials
US Patents and Regulatory Information for MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Santarus | MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE | magnesium hydroxide; omeprazole; sodium bicarbonate | TABLET;ORAL | 022456-001 | Dec 4, 2009 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Santarus | MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE | magnesium hydroxide; omeprazole; sodium bicarbonate | TABLET;ORAL | 022456-002 | Dec 4, 2009 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Santarus | MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE | magnesium hydroxide; omeprazole; sodium bicarbonate | TABLET;ORAL | 022456-001 | Dec 4, 2009 | 6,489,346 | ⤷ Start Trial |
| Santarus | MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE | magnesium hydroxide; omeprazole; sodium bicarbonate | TABLET;ORAL | 022456-002 | Dec 4, 2009 | 7,399,772 | ⤷ Start Trial |
| Santarus | MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE | magnesium hydroxide; omeprazole; sodium bicarbonate | TABLET;ORAL | 022456-002 | Dec 4, 2009 | 6,699,885 | ⤷ Start Trial |
| Santarus | MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE | magnesium hydroxide; omeprazole; sodium bicarbonate | TABLET;ORAL | 022456-001 | Dec 4, 2009 | 7,399,772 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE
See the table below for patents covering MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Argentina | 038157 | FORMAS DE DOSIFICACION DE BENZIMIDAZOLES SUSTITUIDOS Y SU USO | ⤷ Start Trial |
| Austria | 340574 | ⤷ Start Trial | |
| Australia | 1907100 | ⤷ Start Trial | |
| Australia | 2002330863 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1020461 | C300482 | Netherlands | ⤷ Start Trial | PRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMZOUT; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17091/0263 - 0001 20101105 |
| 0124495 | SPC/GB01/006 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727 |
| 1499331 | C300615 | Netherlands | ⤷ Start Trial | PRODUCT NAME: NATRIUMSULFAAT, MAGNESIUMSULFAAT EN KALIUMSULFAAT; NAT. REGISTRATION NO/DATE: RVG 110863 20130417; FIRST REGISTRATION: BE 434323 20130220 |
| 1499331 | 13C0055 | France | ⤷ Start Trial | PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: BE - 434323 20130220 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch